Verastem (NASDAQ:VSTM) CEO Dan Paterson Sells 1,299 Shares of Stock

Posted by Brian Himes on Nov 6th, 2026

Verastem, Inc. (NASDAQ:VSTM – Get Free Report) CEO Dan Paterson sold 1,299 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $9.60, for a total value of $12,470.40. Following the transaction, the chief executive officer owned 651,413 shares of the company’s stock, valued at $6,253,564.80. This trade represents a 0.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dan Paterson also recently made the following trade(s):

On Thursday, October 1st, Dan Paterson sold 44,121 shares of Verastem stock. The shares were sold at an average price of $8.00, for a total value of $352,968.00.

Verastem Stock Performance

Shares of NASDAQ:VSTM opened at $9.38 on Friday. The company has a debt-to-equity ratio of 1.48, a current ratio of 2.25 and a quick ratio of 2.22. The business’s fifty day moving average price is $8.36 and its two-hundred day moving average price is $6.24. Verastem, Inc. has a fifty-two week low of $3.43 and a fifty-two week high of $10.82. The stock has a market capitalization of $849.45 million, a price-to-earnings ratio of -3.53 and a beta of 0.45.

Verastem (NASDAQ:VSTM – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.27). Verastem had a negative net margin of 231.59% and a negative return on equity of 467.49%. The company had revenue of $24.01 million for the quarter, compared to the consensus estimate of $26.57 million. As a group, analysts predict that Verastem, Inc. will post -1.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC acquired a new position in Verastem during the 3rd quarter worth about $122,000. Aries Wealth Management increased its position in Verastem by 6.5% in the 3rd quarter. Aries Wealth Management now owns 32,833 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 2,000 shares in the last quarter. Simplicity Wealth LLC acquired a new stake in Verastem in the 3rd quarter valued at about $89,000. Opaleye Management Inc. acquired a new stake in Verastem in the 2nd quarter valued at about $6,876,000. Finally, Bank of New York Mellon Corp acquired a new stake in Verastem in the 2nd quarter valued at about $706,000. Institutional investors and hedge funds own 88.37% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on VSTM shares. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Verastem in a research note on Monday, October 5th. BTIG Research lifted their target price on shares of Verastem from $18.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, October 15th. Benchmark reissued a “buy” rating on shares of Verastem in a report on Friday, October 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Verastem in a research report on Monday, September 28th. Finally, Wolfe Research began coverage on Verastem in a report on Thursday, September 17th. They set an “outperform” rating for the company. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Verastem currently has a consensus rating of “Moderate Buy” and an average target price of $16.67.

Get Our Latest Stock Report on VSTM

Verastem News Summary

Here are the key news stories impacting Verastem this week:

Positive Sentiment: Verastem’s reported quarterly loss improved from $1.35 per share a year ago, though it remained larger than analysts expected. Zacks report
Neutral Sentiment: CEO Dan Paterson sold 1,299 shares—about 0.20% of his holdings—in a transaction under a pre-arranged Rule 10b5-1 plan, leaving him with more than 651,000 shares. The small, scheduled sale may have limited significance for investors. SEC filing
Neutral Sentiment: The company posted an updated corporate presentation on its oncology programs, but the report provided no specific new developments likely to change the investment outlook. Corporate presentation update
Negative Sentiment: Third-quarter adjusted loss was $0.72 per share, wider than the $0.47-per-share consensus estimate. Revenue of $24.0 million also fell short of expectations of about $26.6 million. The earnings and sales misses are the clearest near-term headwinds for the stock. Third-quarter results

Verastem Company Profile

(Get Free Report)

Verastem, operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. The company’s research is centered on tumors driven by abnormalities in the RAS/MAPK signaling pathway, which can promote cancer-cell growth and resistance to treatment.

Verastem’s leading product candidates include avutometinib, an oral RAF/MEK clamp designed to inhibit signaling within the RAS/MAPK pathway, and defactinib, an oral focal adhesion kinase inhibitor.